Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

ClinicalTrials.gov ID: NCT00192296

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00192296. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528, a Humanized Monoclonal Anti-Interleukin-9 Antibody, in Healthy Adult Volunteers

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase I study to evaluate the safety and tolerability of escalating single IV doses of MEDI-528.

Study identification

NCT ID: NCT00192296
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: MedImmune LLC; Industry
Enrollment: 24 participants

Conditions and interventions

Conditions

Asthma

Interventions

MEDI-528 0.3 mg/kg Biological
MEDI-528 1 mg/kg Biological
MEDI-528 3 mg/kg Biological
MEDI-528 9 mg/kg Biological

Biological

Eligibility (public fields only)

Age range: 18 Years to 49 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 2004 (Type not available)
Primary completion: Feb 2005 (Actual)
Completion: Mar 2005 (Actual)
Last update posted: Mar 6, 2014

2004 – 2005

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
MDS Pharma Services	New Orleans	Louisiana	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00192296, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 6, 2014 · Synced Nov 14, 2026